Seagen’s pipeline includes 11 new molecular entities and would double Pfizer’s early-stage oncology clinical pipeline. A next-generation cytotoxic payload for ADCs is on the way too.
While Pfizer Inc. certainly has its eye on the near-term revenue stream coming from Seagen Inc. ’s four commercial drugs with its proposed $43bn acquisition of the Seattle-based cancer drug developer, a key component of the deal is Seagen’s next-generation antibody-drug conjugates (ADCs) and future potential for combinations.
Seagen represents a rare acquisition opportunity bringing Pfizer a commercial portfolio, a product pipeline and a platform technology. The company...
The China Securities Regulatory Commission has proposed a new “growth tier” for the STAR Market of the Shanghai Stock Exchange, to reinstate the market’s listing standards for unprofitable firms.
Highlights from Day Four of the BIO International Convention include Woodcock offering practical advice on rare disease trials, the sorry state of dealmaking mid-year, Novartis discussing its approach to partnering, and Generate looking for funding to move into Phase III.
While some are calling for Syncona to be wound up, the UK-based company believes many existing and new investors will back the creation of new private fund.
